PDL BioPharma (PDLI) β†’ Stock, financial statements

PDL BioPharma

2.68 USD +0.07 (+2.68%)
Dividends News
  • PDLI Ticker
  • πŸ‡ΊπŸ‡Έ NASDAQ Exchange
  • 87 Employees
4 rated
comming soon
comming soon
comming soon
comming soon
comming soon
comming soon
comming soon
comming soon
comming soon

Financial statements β€” PDL BioPharma

The information is not 100% up-to-date. There may be errors or missing information. Some information is often missing, and, although there are almost no errors, I can't rule them out. Right now, I'm looking for a supplier of high-quality information, but so far what I'm finding is expensive (about $2000 a year). You can help my project here.
19 ← 15 2019 2018 2017 2016 2015
Total Revenue
55M 200M 320M 240M 590M
Cost Of Revenue
54M 48M 31M 4.1M 0
Gross Profit
1.1M 150M 290M 240M 590M
Research and Development
7.3M 3M 7.4M 3.8M 0
Selling General and Admin
54M 63M 63M 40M 36M
Operating Expense
120M 130M 130M 60M 36M
Operating Income
-67M 68M 190M 180M 550M
Other Income Expense Net
0 0 0 0 0
-30M 68M 190M 180M 550M
Interest Income
11M 12M 20M 18M 27M
Pretax Income
-74M -56M 180M 110M 530M
Income Tax
-3M 13M 74M 46M 200M
Minority Interest
-280K 0 -47K 53K 0
Net Income
-70M -69M 110M 64M 330M
Net Income Basic
-70M -69M 110M 64M 330M
19 ← 15 2019 2018 2017 2016 2015
Current cash
190M 390M 530M 170M 220M
Short term investments
15M 19M 14M 77M 3M
66M 85M 85M 150M 58M
40M 19M 9.1M 2.9M 0
Other current assets
15M 19M 14M 77M 3M
Current assets
310M 520M 640M 400M 280M
Long term investments
400M 450M 600M 820M 730M
Property plant equipment
5.5M 7.4M 7.2M 38K 31K
0 0 0 0 0
Intangible assets
290M 430M 570M 630M 400M
Other assets
25M 9.8M 28M 170M 320M
Total assets
720M 960M 1.2B 1.2B 1B
Accounts payable
17M 13M 20M 7M 390K
Current long term debt
0 0 130M 88M 25M
Other current liabilities
28M 39M 47M 35M 11M
Total current liabilities
46M 52M 190M 130M 37M
Long term debt
27M 120M 120M 230M 230M
Other liabilities
49M 43M 86M 97M 51M
Minority Interest
78K 0 0 4.3M 0
Total Liabilities
120M 230M 400M 460M 320M
Common stock
-78M -97M -100M -110M -120M
Retained earning
670M 830M 950M 860M 810M
Treasury stock
0 -2.1M 0 0 0
Capital surplus
β€’ β€’ β€’ β€’ β€’
Shareholder equity
590M 730M 850M 750M 700M
Net tangible assets
300M 300M 280M 120M 300M
19 ← 15 2019 2018 2017 2016 2015
Net Income
-70M -69M 110M 64M 330M
6.3M 16M 25M 12M 0
Changes in receivables
-19M -110K -67M 93M 500K
Changes in inventories
21M 9.8M 6.3M 2.9M 0
Cash change
-200M -140M 360M -53M -73M
Cash flow
32M 13M 41M 100M 300M
Capital expenditures
-760K -4.5M -1.3M -25K -9K
β€’ β€’ β€’ β€’ β€’
Investing activity other
β€’ β€’ β€’ β€’ β€’
Total investing cash flows
22M 57M 460M -140M -80M
Dividends paid
9K β€’ β€’ β€’ β€’
Net borrowings
-180M -290M -300M 77M 34M
Other financing cash flows
β€’ β€’ β€’ β€’ β€’
Cash flow financing
-190M -180M -120M -29M -290M
Exchange rate effect
β€’ β€’ β€’ β€’ β€’

Produces and markets biopharmaceutical products